Pfizer with Johnson and Johnson report Bapineuzumab has performed poorly in study 302 phase III trial of intravenous delivery for individuals with mild to moderate Alzheimer's disease who carry the Apo E4. Apo E4 (Apolipoprotein E Epsilon 4 Genotype) is a linked genetic risk factor for late onset Alzheimers disease.
Bapineuzumab is an antibody focused on removing amyloid beta that is believed to assemble unwanted plaques in the human brain. Pfizer with Johnson and Johnson hoped to market bapineuzumab as a therapy for reducing the symptoms of Alzhiemer's disease.
Individuals participating in the study did not demonstrate the changes in cognition and functional status needed to fair well on the measures selected. Community members will not be able to hang their hat on bapineuzumab as an appropriate therapy for controlling the symptoms of Alzheimers disease.
Home Care Path www.homecarepath.com is a leading senior care provider serving south central Wisconsin. Services include:
-in home staffing and help with ADL's and IADL's
-inpatient advocacy for safe successful hospital stays
-crisis intervention and transitional counseling
-temporary help with a scheduled day surgery
-down sizing home contents when stuff matters
-communicate face to face on the computer across long distances
Simply call 608-432-4286 to schedule an in home interview. 2012 rates are 20.00 per hour. We can be there when you are working. Email lkutzke@homecarepath.onmicorosfot.com We accept long term care insurance. Valuing home and human life. Services are tax deductible.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment